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Abstract 
In recent years Copper-64 in the chemical form of copper chloride 
([64Cu]CuCl2) has been identified as a potential agent for PET imaging and 
radionuclide therapy. The aim of this research was to determine the biodi-
stribution and the labeling of radio nanoparticle with 64CuCl2, the nanopar-
ticles Cu(acac)2/F-TiO2 were mixed with 64CuCl2 (20-37 MBq), then the final 
solution was used to injected healthy Wistar rats to probe the absorption of 
nanoparticle inside tissue trough of the groups OH that are formed during the 
functionalization of the Cu(acac)2/F-TiO2. The “in vivo” evaluation after real-
ize the images study in micro PET equipment, uptake of the radio-nanoparticle 
was observed in the digestive system in the healthy Wistar rats. 
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1. Introduction 
Assumed its half-life and decay scheme, 64Cu (T1/2 = 12.7 h, 17.4% β+, 39% β−, 
43.6% EC) has the potential to serve a dual role in the development of molecular 
agents for PET imaging and radioimmunotherapy drugs in oncology [1]. In this 
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study, small irradiations were performed, demonstrating the feasibility of 64Cu 
production by this method [2] [3]. 64Cu of a high specific activity in the form of 
copper chloride (CuCl2) was produced at the Radiopharmacy Cyclotron Unit of 
the Faculty of Medicine, UNAM by the 64Ni(p,n)64Cu reaction with 11 MeV 
protons as previously reported [1]. After radiochemical purification, the copper 
fraction was evaporated to dryness, and the metal was recovered with a physio-
logical saline solution for injection [3]. The use of 64Cu has dramatically in-
creased in the past decade and its production has now been reported by aca-
demic sources in the United States, Europe, and Japan [4] [5] [6] [7]. 
Developing countries have been performing Emission Tomography (PET) 
scans, first animals and then with patients. Nearest PET of Mexico, it was at Los 
Angeles California University (UCLA). In Mexico the application of diagnostic 
technique began in an academic environment at UNAM in 2002. The institution 
few years later, began to research on animals, as well as provides studies to lo-
calize cancer at public [8]. 
The first reported system for small animal imagining was developed by Pichler 
et al. [8] [9] and used the combination of lutetium oxyorthosilicate (LSO) and 
Avalanche Photon Diodes (APDs) which was the state of the art technology at 
this time. The system had an outer diameter of 120 mm and was placed inside 
the gradient of a 7-T magnetic resonance (MR) imagine scanner, while the radi-
ofrequency coil had an outer diameter of 60 mm and was fitted inside the PET 
ring. Each detector had 19 × 19 mm2 crystal block and each block consisted of a 
12 × 12 array of 1.5 × 1.5 × 4.5 mm3 LSO crystals, each crystal block was placed 
on a monolithic 3 × 3 APD. The system showed very good performance with no 
interference from the magnetic field and reported energy resolution of ~15%. All 
crystal pixels were clearly resolved, and success simultaneous mouse imagine 
was performed [9] [10] [11]. 
A series of new hexadentate and pentadentate chelators were designed and 
synthetized as chelators 64Cu. The new chelators contain different types of donor 
groups and are expected to form neutral complexes with copper (II). This was 
aimed to detect and treat at the same time the cancer. Ewen Bodio et al. [12]. 
propose different compounds tetradentates, where the ligands are joint easily to 
64Cu [13]. 
The aim of this research was to evaluate the radiolabeling and biodistribution of 
a new nanocompound 64Cu-(acac)2/F-TiO2 [14]. The radioactive material was ad-
ministered in three male Wistar rats to visualize biodistribution of this new nano-
radio compound in the organs. This compound will be tested after biodistribution, 
in rats with specific tumors of cancer. 
Across the world, it was tried chelating 64Cu-CuCl2 with molecules containing 
“d” metals of the periodic table through covalent bonds. In addition, porphyrin 
compounds, among others. 
2. Methodology 
Copper production was carried out in a cyclotron (Siemens Eclipse HP) via the 
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reaction 64Ni (p, n) 64Cu 11 MeV proton using 64Ni and electrodeposited on a 
gold disc as a white solid. Three male Wistar rats (195 ± 18 g) were used to vi-
sualize the in vivo whole-body (WB) distribution of the radionuclide by micro-
PET imaging with a Focus 120 instrument (Concorde Microsystems). A series of 
microPET images were acquired with the rats under gaseous anesthesia ((2 - 3)% 
isoflurane) 30 min after injections (p.i.) of 20 - 37 MBq of 64CuCl2. The proce-
dure for labeled nanoparticles was performed using 20 μg of the nanocatalysts, 
which were dissolved in absolute ethanol placing them under constant stirring 
during 10 minutes at 600 rpm. Then the 64CuCl2 (20 - 37 MBq) was added to the 
final solution, at pH ~3. Finally, it were placed in incubation at 85˚C and 450 
rpm, during 30 minutes. After the incubation 200 μL of saline solution (17%) 
was added at pH~5. Healthy rats were intravenously injected with the ra-
dio-nanoparticle solution. The studied rats were treated under protocol of The 
Universidad Nacional Autónoma Metropolitana accepted by COFEPRIS (Mex-
ican FDA) 
3. Results 
The results obtained in this research shown the caption of the radionanoparticle 
this radionanoparticle linked to 64CuCl2 trough of the groups OH (Figure 1), 
that are formed during the functionalization of the Cu(acac)2/F-TiO2. Previous 
works have reported that the marked radionanoparticles have been used linked 
to chelate agent (68Ga, 64Cu and 89Zr) [15]. Then the Cu(acac)2/F-TiO2 acts at the 
same way behavior as chelate agent mixed with 64CuCl2. 
The Cu(acac)2/F-TiO2, acetylacetonate in the copper may have different ar-
rangements. The ligand acetylacetonate in nanomaterial may take different 
structures, depending where is bonding (Figure 2). 
The aqueous-solution coordination chemistry of copper is limited to three 
oxidation states (I, II, III). Due to the lability of most Cu(I) complexes, they typ-
ically lack sufficient kinetic stability for radiopharmaceutical applications, while 
 
 
Figure 1. Functionalized nanoparticles. 
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Figure 2. Copper acetylacetonate with different arrangements. 
 
Cu(III) is very rare and difficult to attain without the use of strong p-donating 
ligands. Therefore, it is easy to incorporate copper acetylacetonate in a matrix of 
Titania sol-gel. 
4. Discussion 
One of the main tests in developing radiopharmaceuticals labeled with 64Cu is 
their in vivo stability important for averting transchelation of copper with the 
many copper chelating proteins present in the blood. 
The most important of this research is: a) verify if the 64CuCl2 linked to the 
new nanoparticle proposed having incorporated copper; b) Achieved the goal a), 
healthy rats are injected with the radioactive solution, it is important verify if ex-
ist any signal. 
The “in vivo” evaluation after realize the images study in micro PET equip-
ment, uptake of the radio-nanoparticle was observed in the digestive system in 
the healthy Wistar rats, as shows the Figure 3. 
The nanoparticle Cu(acac)2/F-TiO2 is functionalized with 24SO
− , 34PO
−  and 
GABA (aminobutyric acid), the final result is a nanomaterial OH saturated [12] 
[14] [15]; it is the ligand which 64CuCl2 is labeled. 
In previous studies, have been proved that elimination of radionuclide is 
trough liver and intestines with little accumulation in the kidneys [11] [16] [17]. 
5. Conclusions 
In this research healthy Wistar rats were used as a control, for the biodistribu-
tion study of 30 min [5]. An uptake of the radio-nanoparticle is observed in the 
digestive system. Nevertheless, the nanoparticle linked to 64CuCl2 is useful for 
purposes. 
Now, it is well known that this system is useful for detecting damaged zones 
while treating those areas. In the references given in the discussion part clearly, 
it illustrates how the nanomaterial of just 10 nm cross-cell barriers. 
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Figure 3. Representative whole body maximum intensity projections of micro PET im-
ages showing the biodistribution of 64Cu(AcAc)2. 
 
Therefore the radioactive properties of 64Cu (T1/2 = 12.7 h, 17.4% β+, 39% 
β−, 43.6% EC) make them ideal candidates for use in theragnostic applications. 
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